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Schwann cells are highly plastic cells that dedifferen-
tiate to a progenitor-like state following injury. How-
ever, deregulation of this plasticity, may be involved
in the formation of neurofibromas, mixed-cell tumors
ofSchwanncell (SC)origin that ariseupon lossofNF1.
Here, we show that adult myelinating SCs (mSCs) are
refractory to Nf1 loss. However, in the context of
injury, Nf1-deficient cells display opposing behaviors
along the wounded nerve; distal to the injury, Nf1/
mSCs redifferentiate normally, whereas at the wound
site Nf1/ mSCs give rise to neurofibromas in both
Nf1+/+ and Nf1+/ backgrounds. Tracing experiments
showed that distinct cell typeswithin the tumorderive
from Nf1-deficient SCs. This model of neurofibroma
formation demonstrates that neurofibromas can orig-
inate from adult SCs and that the nerve environment
can switch from tumor suppressive to tumor promot-
ing at a site of injury. These findings have implications
for both the characterization and treatment of neuro-
fibromas.
INTRODUCTION
Neurofibromatosis type 1 (NF1) is a common autosomal-
dominant inherited disease that affects one in 3,500 people
worldwide. The hallmark of this disease is the development of
neurofibromas—heterogeneous, benign tumors composed of a
mixture of Schwann cells (SCs), axons, ‘‘perineurial-like’’ cells,
inflammatory cells, and vascular cells embedded in a rich extra-
cellular matrix. Neurofibromas can be classified as dermal
(arising exclusively in the skin) or plexiform (developing along
the nerve plexus). Although dermal and plexiform neurofibromas
are similar at the cellular and ultrastructural levels, only the latter126 Cell Reports 5, 126–136, October 17, 2013 ª2013 The Authorscan progress to the highly malignant tumors known as malignant
peripheral nerve sheath tumors (MPNSTs) (Ferner, 2007;
Riccardi, 1992). Despite their mixed-cell composition, neurofi-
bromas have been shown to originate from SCs (the main type
of glia in the peripheral nervous system [PNS]) that have under-
gone biallelic loss of NF1. NF1 codes for neurofibromin, a
Ras-GTPase activating protein (Ras-GAP) that negatively regu-
lates Ras signaling by accelerating the conversion of active
Ras-GTP to inactive Ras-GDP (Martin et al., 1990; Xu et al.,
1990). Loss of neurofibromin leads to hyperactivation of Ras
and its downstream effectors, and accordingly, elevated levels
of Ras signaling are detected in NF1/ SCs isolated from
neurofibromas or MPNSTs and have been shown to be critical
for the maintenance of a transformed phenotype (Basu et al.,
1992; DeClue et al., 1992; Kim et al., 1997).
In the adult, SCs exist in one of two highly quiescent, special-
ized states: myelinating SCs (mSCs), which myelinate larger
axons, or non-mSCs, which bundle together groups of smaller
axons in structures known as Remak bundles (Jessen and
Mirsky, 2005). There is no identified stem cell population in the
nerve to produce new cells; instead, differentiated SCs have
the capacity to dedifferentiate to a progenitor-like state. This
plasticity of SCs is critical for the ability of the PNS to regenerate.
Traumatic injury to the PNS produces acute tissue damage at the
lesion site. Distal to the wound site, the nerve stump undergoes a
series of well-characterized molecular and cellular events known
as Wallerian degeneration (WD). During WD, axons downstream
of the injury site degenerate, leaving behind SCs that dedifferen-
tiate to a progenitor-like state and divide inside their basal
lamina. The dedifferentiated SCs, together with resident and
infiltrating macrophages, clear the axonal and myelin debris,
thereby generating a conducive environment for newly formed
axons. The SCs then organize themselves into cellular cords
that will guide the regrowing axons back to their targets.
This period is associated with a robust inflammatory response:
inflammatory cells, including mast cells, neutrophils, and
T cells, enter the nerve in large numbers, both at the damage
site and throughout the length of the distal stump. Following
axonal regrowth, SCs redifferentiate in response to axonal sig-
nals and the inflammatory response resolves to give rise to a
repaired and functional nerve (Fawcett and Keynes, 1990;
Scherer and Salzer, 2001; Zochodne, 2008). It has frequently
been observed that neurofibromas resemble the ‘‘injured’’ state
in that they are composed of a similar complex mixture of cells
found in the nerve following injury, and the SCs in the tumor
are dedifferentiated and mostly dissociated from axons.
Because of this, neurofibromas have been referred to as ‘‘unre-
paired wounds’’ (Parrinello and Lloyd, 2009; Riccardi, 1992).
Recent work from our laboratory has shown that strong and
sustained activation of the Raf/ERK Ras-downstream pathway
in SCs in vivo is sufficient to induce fully differentiated mSCs to
revert to a progenitor-like state and dissociate from axons
(Napoli et al., 2012; Parrinello et al., 2008). Moreover, we found
that signals from the dedifferentiated SCs orchestrated the
inflammatory response via the secretion of cytokines. Therefore,
a reasonable model of neurofibroma formation suggested that
NF1 loss via elevated Ras/Raf/ERK signaling would be sufficient
to drive many of the early stages of tumor formation.
However, recent mouse models have contradicted this simple
model. Loss of Nf1 in SCs during development resulted in the
formation of normal nerves, although tumors developed in adult-
hood, whereas loss of Nf1 in adult SCs did not result in frequent
tumor formation (Joseph et al., 2008; Le et al., 2011; Wu et al.,
2008; Zheng et al., 2008). These results suggested that in the
context of the nerve, Nf1 loss does not affect the ability of SCs
to interact with axons or differentiate, and indicated that Nf1
needed to be lost at a specific stage during development to
‘‘prime’’ the SC for later tumor development triggered by rare
later events (Parrinello and Lloyd, 2009). Moreover, other cell
types also appeared to be important for the development
of neurofibromas, as tumors frequently developed only in a
Nf1+/ background, suggesting that other Nf1+/ cell types are
required for tumor formation (Yang et al., 2008; Zhu et al., 2002).
Here, we analyzed the effect of Nf1 loss in adult mSCs. We
found that Nf1 loss was unable to induce ERK activation in adult
mSCs, had no effect on the structure of the nerve, and did not
result in tumors. However, we found that following injury, Nf1-
deficient mSCs formed neurofibromas specifically at the wound
site. Interestingly, these tumors formed with a similarly high
frequency in both Nf1+/ and Nf1+/+ backgrounds. These
results show that adult mSCs can be the ‘‘cell of origin’’ for
neurofibromas. Moreover, they demonstrate that the tumor-
suppressive environment of the nerve can be converted to a
tumor-promoting environment at a wound site that cooperates
with Nf1/ SCs to form a neurofibroma. They also identify an
alternative mouse model for neurofibroma formation that should
be useful for studying the early stages of tumor formation and
identifying novel therapeutic strategies.
RESULTS
Targeting Loss of Nf1 in Adult mSCs
To test the effects of Nf1 loss in adult mSCs, we selected a
conditional transgenic mouse line expressing the tamoxifen
(Tmx)-inducible Cre recombinase (Cre-ERT2) under the controlCof an SC-specific promoter, P0, which has been shown to be
highly specific for mSCs (Leone et al., 2003; Messing et al.,
1992, 1994). To confirm the specificity of Cre-ERT2 expression
and determine the efficiency of recombination, we initially
crossed the P0-CreER mice to Rosa26-YFP reporter mice
(P0:YFP). The progeny were treated with Tmx for 5 consecutive
days and 15 days later, sciatic nerve cryosections were immuno-
stained for yellow fluorescent protein (YFP) and either the mSC
marker, P0, or the non-mSC marker, p75. As shown in Figures
1A and 1B, the specificity of recombination appeared to be
highly specific formSCs, as the only detectable YFP+ cells within
the sciatic nerve were also P0+. This specificity was confirmed in
multiple nerves and sections in which we failed to find a single
p75+/YFP+ cell (Figure 1B) or a single YFP+/P0 cell, confirming
that recombination was not only restricted to SCs but also
confined to mSCs. The efficiency of recombination, as deter-
mined by counting the percentage of P0+ cells that were positive
for YFP, was variable between animals, ranging from a minimum
of 15% to a maximum of approximately 50% (Figure 1C). Next,
P0-CreER mice were mated with Nf1fl/fl (Zhu et al., 2001) and
Nf1fl/ (Brannan et al., 1994) mice to generate both P0-Nf1fl/fl
and P0-Nf1fl/ mice. Nf1fl/fl and Nf1fl/ mice were used as con-
trols, as aNf1+/ genetic background has been shown to be crit-
ical for tumor formation in some NF1 mouse tumor models (Le
and Parada, 2007; Zhu et al., 2002). Two weeks following Tmx
treatment, recombination was confirmed by PCR (not shown)
and neurofibromin expression was analyzed by western blot,
which showed a significant loss of neurofibromin expression in
the P0-Nf1fl/fl and P0-Nf1fl/ mice (Figure 1D).
Loss of Nf1 in Adult mSCs Fails to Activate ERK
Signaling or Stimulate Proliferation
To determine the effects of Nf1 loss in adult mSCs, we initially
analyzed the sciatic nerves 15 days after the first Tmx injection.
We analyzed the number of p75+ cells, which as a marker of
dedifferentiated SCs would indicate that SC dedifferentiation
had taken place, and performed an analysis of 5-ethynyl-20-
deoxyuridine (EdU) incorporation to detect aberrant proliferation
(Figure 1A and S1A). In both cases, we were unable to detect dif-
ferences between controls and Nf1 mutants, indicating that Nf1
loss does not induce a rapid induction of SC dedifferentiation
and/or proliferation (Figures 2A and S1A). To determine whether
Nf1 loss in adult SCs led to changes in the structure of the nerves
over the longer term, as was seen in mice in which Nf1 was
knocked out in SCs during development, we analyzed the struc-
ture of the nerves at 8 months following Nf1 deletion. Analysis of
semithin sections of the sciatic nerves showed no detectable
differences in the structure of myelinated axons between Nf1
mutants and controls (Figure 2B). Moreover, ultrastructural anal-
ysis of mutant and control animals revealed normal Remak bun-
dles (Figure S1B), which were the first indicators of the initiation
of hyperplasia in other NF1 model mice (Wu et al., 2008; Zheng
et al., 2008), and the lack of an inflammatory response (Figures
S1C and S1D). Furthermore, no tumors were observed in >60
animals for up to 15 months following the Tmx injections.
Consistent with the lack of any phenotype, we could not detect
any alteration of ERK activation in Nf1mutants either by western
blot analysis of sciatic nerve lysates (Figure 2C) or byell Reports 5, 126–136, October 17, 2013 ª2013 The Authors 127
Figure 1. P0;Cre-Recombinase Activity Specific to mSCs Induces Neurofibromin Loss
(A) Sciatic nerve cryosections of P0:YFPmice following vehicle (i) or Tmx treatment (ii and iii) were labeled with DAPI, P0, and YFP antibody to identify Cre+mSCs.
(B) Cryosections of Tmx-treated P0:YFP animals were labeled for YFP and the nonmyelinating/dedifferentiated SC marker p75. No colocalization was found in
intact nerves (i and ii). As a positive control, iii shows an injured nerve from Tmx-treated mice in which dedifferentiating YFP+ cells were found to colocalize with
p75 staining (white arrowheads) 7 days after nerve transection.
(C) Graphs show quantification of the percentage of P0+/YFP+ cells (n = 6 animals for each group; ten different fields were counted for each section, and three
sections were counted for each animal; graphs show mean values ± SEM).
(D) Western blot analysis of neurofibromin expression in mouse sciatic nerve lysates 15 days after Tmx administration.immunofluorescence of sciatic nerve sections (Figure 2D).
Therefore, Nf1 deletion in adult mSCs is not sufficient to activate
Ras/ERK signaling or induce a phenotypic or tumorigenic
response.
Neurofibromas Develop Specifically at a Wound Site
In mice in which Nf1 is knocked out during development, the
nerves develop normally. However, as the mice age, the struc-
tures of the nerves show abnormalities, with SCs dissociating
from axons, and the mice eventually develop tumors, indicating
that additional, possibly environmental, signals are involved (Wu
et al., 2008; Zheng et al., 2008). We decided to test whether
wounding of the sciatic nerve might cooperate with loss of Nf1
to induce tumorigenesis, as we reasoned that (1) it would cause
activation of ERK signaling and dedifferentiation of all SCs distal
to the wound, which might provide a pool of proliferating Nf1/
SCs from which a tumor could develop; and (2) it would trigger a
potent inflammatory response along the length of the nerve and
might thus provide a protumorigenic environment. We therefore
performed partial transections of the right sciatic nerve 15 days
following Tmx treatment in both P0-Nf1fl/fl and P0-Nf1fl/ mice
and the corresponding Nf1fl/fl and Nf1fl/ controls. Six to
8 months following injury, the animals were sacrificed and
analyzed for changes to the structure of the nerves and tumor
formation (Figure 3A). Upon gross dissection, similar high pro-
portions of both P0-Nf1fl/fl and P0-Nf1fl/ mice exhibited visible
tumors at the injury site (33.3% and 34.6%, respectively), indi-128 Cell Reports 5, 126–136, October 17, 2013 ª2013 The Authorscating that Nf1 loss in mSCs is able to cooperate with a wound-
ing response to induce tumor formation. These results also
showed that the Nf1 genetic background did not contribute to
the rate of tumor formation in this mouse model (Figures 3B
and 3C). In contrast, the control animals displayed apparently
well-regenerated sciatic nerves. A single exception was one
Nf1fl/ mouse, which had a microscopically enlarged nerve.
Given the rarity of this event and the fact that it occurred in a
heterozygous background, it is tempting to speculate that this
tumor may have resulted from loss of heterozygosity at the Nf1
locus. The unwounded contralateral nerves of the Nf1 mutants
were also unaffected in that they were indistinguishable from
uncut controls, arguing against a possible systemic contribution
to tumor formation.
The structure and composition of the tumors that developed in
Nf1-deficient mice were characterized and compared with the
equivalent region of control animals at 8 months following injury.
Cross-sections of the nerve showed a remarkable enlargement
of the peripheral nerves in Nf1-deficient mice compared with
controls (Figures 3C and S2A), with Hoechst staining showing
an increase in cell density in the mutant nerves (Figure S2B).
Histological examination of the sciatic nerves by our pathologist
revealed that the tumors that developed in themutantmice could
be classified as GEM grade I neurofibromas (Stemmer-
Rachamimov et al., 2004). Hematoxylin and eosin (H&E) staining
showed that the tumors were composed of increased numbers
of disorganized spindle-shaped cells, infiltrating mast cells,
Figure 2. Nf1 Loss in mSCs Does Not Alter the Sciatic Nerve
(A) Fifteen days after the first Tmx dose, 5- to 6-week-old P0-Nf1fl/fl and P0-Nf1fl/ mutants and Nf1fl/fl and Nf1fl/ control mice were treated with Tmx and their
sciatic nerveswere harvested for analysis. Nerves were processed for immunostainingwith p75 antibody to label nonmyelinating/dedifferentiated SCs. The graph
shows quantification of p75+ cells per field of view (n = 3 animals for each group; eight fields were counted per section, with three sections per animal; data are
represented as mean values ± SEM).
(B) Representative phase-contrast images of toluidine-blue-stained, semithin cross-sections of sciatic nerves from controls (upper panels) and Nf1 mutants
(lower panels) 8 months after Tmx administration. Scale bar is 10 mm.
(C) Western blot analysis of sciatic nerve extracts 15 days after induction ofNf1 loss shows no alteration of p-ERK levels uponNf1 loss (third and fourth lanes). On
the right, nerve extracts from control mice 24 hr after nerve transection are shown as a control for ERK activation.
(D) Representative images of cross-sections of sciatic nerves immunostained for p-ERK (red) and P0 (green; n = 3 for each group).
See also Figure S1.and other inflammatory cells in a collagen-rich matrix, and
resembled neurofibromas seen in other GEM models of neurofi-
broma formation (Figure 3D; Cichowski et al., 1999; Le et al.,
2011; Wu et al., 2008; Zheng et al., 2008). Moreover, the tumors
were also positive for S100, although the levels were lower than
those found within the uninjured part of the nerve (Figures S2C
and S2D). Early examination of nerves at 3 months showed
that the mutant nerves had small tumors that continued to
grow and eventually gave rise to the larger tumors seen at
6–8 months. In addition, a proportion of these tumors (10%)
progressed along the distal stump of the nerve, consistent with
the neoplastic nature of these tumors (Figure S2E). EdU-labeling
experiments showed increased proliferation rates within the
tumor regions compared with those seen in regenerated control
nerves, and some of these proliferating cells were SCs (Figures
S3A–S3C). Structural analysis of semithin and ultrathin
sections confirmed the differences in structure between theCregenerated control nerves and the tumors that formed in the
Nf1 mutant mice. Repaired sciatic nerves from control mice
were tightly packed with myelinating axons, with little
intervening space, and electron microscopy (EM) analysis
showed well-organized minifascicles, which form as part of the
regeneration process (Figure S3D). There were also no discern-
ible repair abnormalities in the Nf1+/ mice, which although pre-
viously reported to exhibit skin wound-repair defects (Atit et al.,
1999), appeared able to repair nerves normally. In contrast, the
tumors in the Nf1 mutants resembled neurofibromas seen in
other mouse models (Cichowski et al., 1999; Wu et al., 2008).
They had a highly disorganized structure with a significantly
expanded interstitial compartment with increased cellularity
between myelinated axons. EM analysis revealed numerous
denervated SCs, fibroblasts, ‘‘perineurial-like’’ cells, mast cells,
and the occasional ‘‘naked’’ axon in a dense collagen matrix
(Figures 3E, 3F, and S3D). Consistent with the mixed-cellell Reports 5, 126–136, October 17, 2013 ª2013 The Authors 129
Figure 3. Nf1 Mutant Mice Form Tumors at
the Site of Injury
(A) Schematic representation of the protocol used
to assess the effect of injury.
(B) Table shows the frequency of tumor develop-
ment in the four genotypes studied.
(C) Micrographs show sciatic nerves (uninjured
nerves [top panels]) and injured nerves [bottom
panels] of age-matched controls (i and ii) and
NF1 mutants (iii and iv) Tmx-treated animals,
8 months following injury. Quantification of the
size of the tumors, calculated from sections of
the tumors, showsmean relative area ±SEM (n = 3
for each genotype).
(D) Control and NF1 mutant mice were sectioned
longitudinally and stained with H&E. i: uncut con-
trol; ii: control nerve Nf1fl/fl 8 months after injury
shows fairly well aligned nuclei, features that are
consistent with regeneration. iii: NF1 mutants
developed neurofibromas at the injury site. Note
the disordered, convoluted bundles of cells
exhibiting spindle-cell morphology with ovoid and
spindle-shaped nuclei, features that contrast with
the regenerative appearance of the cells in ii.
(E) Representative EM image of a P0-Nf1fl/fl tumor
shows a mixture of intact mSCs (arrow), dissoci-
ated SCs, ‘‘perineurial-like’’ cells, and mast cells
(arrowhead).
(F) Representative image of an SC, identified by a
continuous basal lamina (black arrows), found
within a P0-Nf1fl/fl tumor. The white arrow points to
a naked axon; abundant collagen deposits are
also observed.
See also Figures S2, S3, and S4.composition of these tumors, immunostaining showed a
large increase in the numbers of mast cells, macrophages, neu-
trophils, and T cells within the tumors compared with the regen-
erated regions of the control nerves, and activated fibroblasts
were found in the tumors but never in the regenerated nerves
(Figure S4).
Nf1-Deficient Cells in the Tumor Are Frequently
S100 and Can Resemble Perineurial Cells
To define the contribution of Nf1-deficient cells in the neurofi-
bromas formed at the injury site, we took advantage of a floxed
YFP reporter and crossed it to the P0-Nf1fl/fl and P0-Nf1fl/
mutants. Tumors were dissected from these animals 6 months
following injury and processed for immunostaining. YFP analysis
showed a near uniform distribution of Nf1-deficient cells
throughout most tumor sections. The majority of the cells were130 Cell Reports 5, 126–136, October 17, 2013 ª2013 The AuthorsYFP+ and most appeared to be dissoci-
ated from axons (Figure 4A). Moreover,
the YFP+ cells expressed p75, a marker
ofdedifferentiated/non-mSCs (Figure4B),
thus clearly demonstrating that loss of
Nf1 in mSCs in the context of a wound
results in the maintenance of these cells
in their ‘‘progenitor-like’ state, dissocia-
tion from axons, and abnormal pro-
liferation. Indeed, in some tumors, thisabnormal behavior included invasion of YFP+ cells into adjacent
muscle (Figure 4A).
The ability to ‘‘mark’’ the cells derived from recombined
mSCs enabled us to make several observations concerning
the ‘‘neoplastic’’ cells within the tumors with relevance to the
pathology of the tumors. The first observation was that,
although expression of the SC marker S100 is commonly
used as a diagnostic criterion of neurofibromas, we found that
the YFP+ cells within the tumor were mostly negative for
S100. Instead, S100 expression was mostly restricted to intact
mSCs, both scattered throughout the tumor and associated
with the unwounded regions (Figure 4C). These results were
consistent with the low levels of S100 staining seen in
paraffin-embedded tumors, which showed low levels of
S100+ cells within the tumor but high levels within the undam-
aged part of the nerve (Figure S2C).
Figure 4. In the Neurofibromas, the Majority
of Cells Derive from Nf1/ mSCs and Are
S100 and p75+
(A) Representative cross-sections of a neurofi-
broma dissected from a P0:YFP-Nf1fl/fl animal
6 months after Tmx treatment and nerve wound-
ing, and immunolabeled for neurofilament (red)
and YFP (green). Note that the YFP+ cells are
devoid of axonal contact and arrows point to YFP+
cells invading the adjacent muscle tissue.
(B) Immunofluorescence of cross-sections of a
neurofibroma showing colocalization between
YFP (staining Nf1/ SCs) and p75 (dediffer-
entiated/nonmyelinating SCs). Note that nearly all
of the YFP+ cells are positive for p75.
(C) Neurofibroma cryosections from a P0-YFP-
Nf1fl/fl mouse were immunolabeled for YFP (green)
and S100 (red), with nuclei counterstained with
Hoechst (blue). Panels i and ii are representative
images of the neoplastic region and show
that the majority of the YFP+ cells are S100.
Panels iii and iv were taken from the ‘‘regenerated
area’’ and show that the majority of cells
are S100+. The white arrow points to a YFP+/
S100+ cell.
(D) Representative EM image of a perineurial-like
cell in a tumor from a P0-Nf1fl/fl animal. Arrows
point to patchy basal lamina and intracellular
vesicles that are characteristic of these cells.
See also Figure S5.The second observation was that some of the YFP+ cells
within the tumor exhibited themorphology traditionally attributed
to ‘‘perineurial-like’’ cells, which commonly make up a high pro-
portion of neurofibromas (Figures 4B and S5B; Erlandson, 1985).
These extremely thin cells exhibit long cytoplasmic processes
enwrapping other cells and could be seen in all the tumors, albeit
at varying frequency both between and within the tumors
(compare the upper and lower panels of Figure 4A), which is
consistent with a study of human neurofibromas (Lassmann
et al., 1976). A comparison of immunofluorescence images and
EM micrographs revealed a striking resemblance between
many of the YFP/p75-expressing cells and cells that are
frequently found in EM images of neurofibromas and traditionally
are identified as ‘‘perineurial-like’’ (Figures S5A and S5B; Erland-
son, 1991). Moreover, ultrastructural analysis showed that these
cells contained multiple pinocytic vesicles and a partial base-
ment membrane that is characteristic of these cells (Figures 4D
and S5A). This suggests that despite their distinct ultrastructural
morphology, many of these cells are derived from mSCs andCell Reports 5, 126–136,contribute to the neoplastic potential of
the tumor. To characterize these cells
further, we used two markers of peri-
neurial cells, Glut1 and epithelial mem-
brane antigen (EMA). In control nerves,
we were able to show that Glut1 specif-
ically stained the perineurial cells and
the blood vessels (Figure S5B); however,
consistent with other studies, we could
not detect any EMA+ cells within the
mouse nerve (Takebe et al., 2008). Incontrast, within the tumors we detected multiple Glut1+ cells.
Consistent with the observation that some of the YFP+ cells
resembled perineurial cells, a proportion of the YFP+ cells with
a perineurial-like morphology were positive for Glut1 (Fig-
ure S4D). However, only a proportion of these perineurial-like
cells were YFP+, which suggests that ‘‘normal’’ perineurial cells,
or possibly pericytes, are also behaving abnormally andmake up
a significant component of the tumor. Finally, we were able to
identify rare YFP+ cells that were negative for both S100 and
p75 markers, suggesting that neurofibromas may contain rare
cell populations derived from P0+ mSCs that have lost their
original identity (Figure S5B). In contrast to the homogeneous
distribution of YFP+ cells in neurofibromas, only a few positive
cells were found at the injury site in controls (Figure S5E).
Distal to theWound Site,Nf1-Deficient SCs Remyelinate
Normally
An important observation was that tumors only develop at the
wound site. After nerve injury, strong Ras-Raf-ERK activationOctober 17, 2013 ª2013 The Authors 131
Figure 5. Distal to the Wound Site, Nf1/ SCs Redifferentiate and
Nerves Regenerate Normally
(A) Photographs showing the injured and the contralateral uninjured nerves of
control (i) andNf1mutant (ii) mice 8months following Tmx treatment and nerve
partial transection.
(B) Representative phase-contrast images of semithin sections stained with
toluidine blue (i and iii) and EM images (ii and iv) of control (left) and NF1fl/fl
(right) mice.
(C) Sections were prepared from the nerve region distal to the neurofibromas
formed in Nf1 mutants (upper panel) and the equivalent region of control
wounded nerves (lower panel) and immunolabeled for S100 (red) and YFP
(green).
(D) YFP+Nf1/ SCs are found associated with large caliber axons (immuno-
stained for neurofilament in red) 6 months following Tmx treatment and partial
nerve transection.
See also Figure S4.followed by dedifferentiation and proliferation is seen in all SCs at
the wound site and throughout the entire distal stump.Moreover,
there is a robust inflammatory response throughout the length of132 Cell Reports 5, 126–136, October 17, 2013 ª2013 The Authorsthe distal stump. To determine the structure of the regenerated
nerves in the control and mutant nerves, we performed a struc-
tural analysis, which showed that distal to the injury, control and
mutant mice nerves regenerated to a similar extent and were
indistinguishable (Figures 5A and 5B). These results indicated
that, in contrast to thewound site, in the environment of the distal
nerve stump, Nf1/ SCs appeared to behave normally. How-
ever, as we only achieved a maximum of 50% recombination,
a separate possibility was that Nf1/ SCs failed to reassociate
with the regenerating axons and as a result died or were other-
wise lost from the nerve. To exclude this possibility, we exam-
ined the fate of Nf1/ SCs (YFP+) in the distal region of mutant
mice in which tumors had developed at the wound site. In sharp
contrast to what we encountered at the tumor site, we found that
nearly all YFP+ cells were associated with axons and expressed
S100 (Figures 5C and 5D). Many were myelinating, indicating
they had returned to their original fate; however, the occasional
YFP+ cell was found to be p75+ and associated with axons, sug-
gesting that Nf1/ mSCs were capable of differentiating to the
nonmyelinating cell type following an injury. These results
demonstrate that an identical genetic insult to a specific target
cell can have distinct outcomes depending on the microenviron-
mental context. In the distal stump of the nerve, the environment
is tumor suppressive, with dedifferentiated SCs reassociating
with regrowing axons and undergoing redifferentiation. In
contrast, at the wound site the environment is tumor promoting.
However, consistent with a role for the ERK signaling pathway in
maintaining the dedifferentiated state and driving SC prolifera-
tion, sustained elevated levels of ERK signaling were detected
specifically at the wound site in the Nf1mutant animals. Western
blot analysis showed that in contrast to control animals, in which
P-ERK levels returned to low levels by day 5 after injury, the
P-ERK levels remained high in the mutant nerves (Figure 6A).
Moreover, immunostaining showed that the elevated signaling
was confined to the injury site from which the tumor developed,
and was associated with increased proliferation of Nf1/ cells
specifically at the wound site (Figures 6B and 6C).
DISCUSSION
Identifying the ‘‘cell of origin’’ fromwhich tumors can or do derive
has been the aim of many recent animal models of cancer. The
results have been diverse, with cancers shown to be capable
of arising from stem cell and progenitor populations but also
sometimes from fully differentiated cell types (Visvader, 2011).
In NF1-associated neurofibromas, the picture is similarly com-
plex. A series of mouse models in which Nf1 was specifically
deleted from the SC lineage at various developmental stages
indicated that for tumors to occur, Nf1 had to be lost during a
specific developmental window at approximately embryonic
day 13 (Joseph et al., 2008; Wu et al., 2008; Zheng et al.,
2008). However, the tumors only developed later in adulthood
and appeared to derive from the nonmyelinating population. In
contrast, in a separate study, transplant experiments suggested
that dermal neurofibromas could derive from neural-crest-like
stem cells termed skin-derived precursors (SKPs) (Le et al.,
2009). In this study, we used a highly specific promoter to delete
Nf1 from mSCs in adult mice to determine whether these highly
Figure 6. ERK Signaling Is Deregulated in
Sciatic Nerves of Nf1-Deficient Mice
following Injury
(A) Western blot analysis of sciatic nerves from
control (Nf1fl/fl and Nf1fl/) and Nf1 mutant (P0-
Nf1fl/fl and P0-Nf1fl/-) mice at the indicated time
points after injury. Note that the ERK signal is
sustained at day 7 in mutant mice (blot represen-
tative of four different animals for each genotype).
(B) Seven days after injury, cryosections of sciatic
nerves were immunolabeled for the mSC marker
P0 (green) and p-ERK (red). Nuclei were counter-
stained with DAPI. Upper panel: site of injury;
bottom panel: distal region. ERK pathway activa-
tion is sustained only at the site of injury in Nf1
mutants (representative images of three animals
analyzed for each group).
(C) EdU incorporation was assessed 7 days after
injury in control andmutantmice at the site of injury
(left) and distal to the injury site (right). Results
show the means of EdU+/YFP+ cells ± SEM (n = 3
of each group); *p < 0.05.specialized, quiescent cells can give rise to neurofibromas. We
found that, alone, loss of Nf1 in mSCs had no effect on nerve
structure and did not result in tumor formation. However, neuro-
fibromas formed with high efficiency following damage to the
Nf1-depleted nerve. Although these results do not address
whether tumors can derive from adult non-mSCs, they clearly
demonstrate that adult mSCs can be the ‘‘cell of origin’’ for neu-
rofibromas, and that cooperating microenvironmental signals
found only at the wound site are essential for tumors to form.
The finding that tumors only develop at the wound site has
several important implications. Following a nerve injury, mSCs
dedifferentiate along the length of the nerve in response to a sus-
tained signal through the ERK signaling pathway and there is aCell Reports 5, 126–136,robust inflammatory response along the
length of the nerve. The fact that tumors
only form at the injury site shows that
robust activation of ERK signaling, dedif-
ferentiation and proliferation of SCs, and
an inflammatory response is not suff-
icient to trigger tumor formation but that
tumor formation also requires the specific
microenvironment of the wound site.
While an important question that remains
to be resolved involves the nature of these
cooperating signals at the wound site, an
equally important question is, why do
Nf1/ SCs behave normally within the
distal stump of the nerve, acting as wild-
type cells to remyelinate the regrown
axons? The ‘‘tumor-suppressive’’ envi-
ronment of the nerve is further indicated
by the earlier studies in which Nf1 was
deleted from SCs during embryogenesis.
In these studies, the Nf1/ SCs behaved
more or less normally to form both Remak
Bundles and myelinated axons (Wu et al.,2008; Zheng et al., 2008). It was only during adulthood that slight
defects in theRemak bundles could be observed, and it was sug-
gested that tumors derived from these destabilized structures.
Although these studies suggested that tumors derive from adult
non-mSCs, their models are somewhat similar to ours in that
the destabilization of the Remak bundles resembles aspects of
the injured state artificially induced in our model. Consistent
with this idea, tumor formation was associated with an early
inflammatory response. It is possible that tumors developed
from the nonmyelinating population because loss of Nf1 at that
specific developmental stage specifically affected the stability
of Remak bundles, and that tumors could also develop from
mSCs in these mice if they were injured. The finding that loss ofOctober 17, 2013 ª2013 The Authors 133
Nf1 in adult SCsdoes not result in efficient tumor formation is also
consistentwith a separate study inwhichNf1wasdeleted in adult
SCs and tumors only arose in rare cases in older animals (Le et al.,
2011). It is not an unlikely scenario that tumors arose in these
animals following a naturally occurring traumatic injury.
The tumor-suppressive environment of the nerve is further
highlighted by observations that in vitro, Nf1 loss in SCs is suffi-
cient to induce a Ras-like phenotype and elevated Ras/Raf/ERK
signaling that inhibits SC–axonal interactions and blocks SC
differentiation, indicating that neurofibromin is a limiting GAP in
the in vitro environment (Napoli et al., 2012; Parrinello et al.,
2008). This must mean that within the nerve, either neurofibromin
is not a limiting GAP or the environment can act to suppress the
ERK signaling pathway. Moreover, it might also suggest that the
tumor-promotingwound environmentmimics the in vitro environ-
ment,which is consistentwith the view that in vitro culture reflects
an in vivo wounded response (Iyer et al., 1999). It will be crucial to
dissect themechanisms involved, as identification of both tumor-
suppressive and tumor-promoting signals will lead to useful
therapeutic targets that could potentially prevent the develop-
ment of tumors both during development and in adulthood.
A link between wounding and tumorigenesis has long been
recognized (Balkwill and Mantovani, 2001; Martins-Green
et al., 1994). Recent mouse models in the pancreas and skin
have shown that an injured or chronically inflamed environment
is a critical cooperating event with specific genetic changes in
order for tumors to occur, and these models have parallels to
human diseases in which chronic tissue damage can precede
tumor formation (Arwert et al., 2012; Guerra et al., 2007; Kasper
et al., 2011; Wong and Reiter, 2011). Importantly, there is a long-
standing clinical hypothesis that neurofibroma formation is
fostered by local trauma and injury, and hence neurofibromas
are often referred to as unrepaired wounds. Our results are
consistent with this hypothesis and indeed suggest that a neuro-
fibroma could be considered as an ‘‘exaggerated or neoplastic
neuroma’’—an unrepaired ‘‘wound’’ of the peripheral nerve
(Lassmann et al., 1976; Riccardi, 1992, 2007). Because NF1
patients are born heterozygous for NF1, with the loss of the sec-
ond allele, a bottleneck event for neurofibroma formation, injury
is likely to increase the frequency of this event by inducing SC
proliferation. Importantly, however, our results indicate that
injury may play an additional role by creating a protumorigenic
microenvironment required by NF1-deficient cells to induce
tumorigenesis. To determine whether this is the case, it will be
important to define the nature of the protumorigenic environ-
ment, establish whether it is induced by the more common types
of human nerve injuries (e.g., crush injuries), and determine a link
to tumorigenesis in patients with such injuries.
A fascinating observation in a previous model of NF1 is that
tumors only develop in a Nf1+/ background, implicating other
Nf1+/ cell types, in particular mast cells, in neurofibroma forma-
tion (Yang et al., 2008; Zhu et al., 2002). In contrast, we found that
theNf1 background had no effect on the rate of tumor formation,
given that tumors formed with similar efficiencies in both Nf1+/+
and Nf1+/ mice. The mechanism proposed by the previous
studies is that mast cells cooperate with Nf1/ SCs to form
tumors, and that Nf1+/ mast cells are more efficiently attracted
to signals from Nf1/ SCs (Yang et al., 2003). One possible134 Cell Reports 5, 126–136, October 17, 2013 ª2013 The Authorsexplanation for the discrepancy with our results is that thewound
site attracts sufficient wild-type mast cells and that these cells
are capable of cooperating in tumor formation. It will be impor-
tant to test this theory in a mast-cell-negative mouse.
The ability to track the Nf1/ cells derived from mSCs
permitted us to make observations that may have important
clinical implications. Nf1/ mSC-derived cells were a major
component of the tumors that developed at the injury site. Sur-
prisingly, however, we observed that the majority of the YFP+
Nf1/mSC-derived cells within the tumor region were negative
for the SC marker S100, which is commonly used to diagnose
these tumors. Instead, the S100+ cells within the tumor were
mostly YFP and appeared to be the result of normal SCs within
the tumors, as they appeared to be interacting mostly with
axons. This is reminiscent of previous observations made by
Cichowski et al. (1999) in neurofibromas in a Nf1+/;Nf1/
chimeric mouse model, and may be consistent with the often
low levels of S100 seen in human tumors (Hirose et al., 2003;
Tucker et al., 2011). Importantly, the analysis of YFP+/S100/
p75+ cells also revealed that a number of these mSC-derived
cells appeared to be morphologically distinct from SCs. Instead,
they exhibited a characteristic morphology (a long cytoplasmic
process displayed in arrays or enwrapping other cells) associ-
ated with ‘‘perineurial-like’’ cells, which are a frequent cellular
component of neurofibromas and are often considered to be of
fibroblast origin. However, it was previously speculated based
on ultrastructural studies that these cells could derive from
SCs, as frequent ‘‘transitional’’ cells with shared SC/perineurial
features were observed (Erlandson, 1991). Our results indicate
that some of these cells most likely originate from NF1/ SCs
and are likely to be key drivers of the tumor.
In summary, our results demonstrate that neurofibromas can
originate from adult mSCs following loss of Nf1. However, tumor
formation requires a protumorigenic environment that can be
provided by signals specifically found at the site of a nerve injury.
In contrast, these results indicate that, normal nerves constitute
a tumor-suppressive environment. This mouse model gave us
the opportunity to track the fate of Nf1/-induced mSCs, which
led to the important observation that these cells give rise to both
S100 tumor cells and tumor cells with a ‘‘perineurial-like’’
morphology. In future studies, investigators will be able to
track the initial development of these tumors and identify mech-




Nf1flox/flox (Zhu et al., 2001) and Nf1floxl/ (Jacks et al., 1994) on a mixed 129/
Bl/6 background were crossed with P0CreERT2 C57Bl/6 mice (Leone et al.,
2003) to generate P0-Nf1fl/fl and P0-Nf1fl/ mice. P0-Nf1fl/fl and P0-Nf1fl/
mice were bred to LacZRosa (Soriano, 1999) and to YFPRosa (Soriano, 1999).
Tmx Treatment and Nerve Partial Transections
Tmx (Sigma) was dissolved in sunflower oil at 20 mg/ml and filtered through a
0.2 mm filter. Control and Nf1 mutant mice (5–6 weeks old) received intraperi-
toneal injections of 2 mg of Tmx once a day for 5 consecutive days. Fifteen
days after the first Tmx injection, the mice were anesthetized with isoflurane
and the right sciatic nerve was exposed at the sciatic notch. The nerve was
half-transected using scissors, so that the perineurium was breeched and
approximately half of the axons were severed within each nerve. The wound
was then closed with clips. The entire nerve and the unwounded contralateral
were recovered at the indicated time points following surgery. Nerves were
immediately fixed in 4% paraformaldehyde for immunohistochemistry or
frozen in liquid nitrogen for protein analysis.
Cell Proliferation Assay
Cell proliferation was measured by EdU incorporation (Invitrogen). Mice were
pulsed with 1 mg of EdU at 5 hr before sacrifice. The sciatic nerves
were dissected and processed for immunofluorescence. Nerve sections
were then stained using the Click-iT EdU cell proliferation assay kit (Invitrogen)
according to the manufacturer’s instructions.
Statistical Analysis
The data are represented as mean values ± SEM. One-way ANOVA with
Bonferroni post hoc test was used for statistical analysis, and p values
considered significant were indicated by asterisks as follows: *p < 0.05,
**p < 0.01, and ***p < 0.001.
For further details regarding the materials and methods used in this work,
please see the Extended Experimental Procedures.
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